Genedrive making “good progress” as it hurtles towards commercialisation of its hep C test

It was a busy second half of 2017 for Genedrive, which managed to secure a CE mark of its HCV ID Kit, bring on board a distribution partner and launch the test in Africa

It is an “exciting period of growth” for Genedrive PLC (LON:GDR) according to its boss, David Budd, as the medical diagnostics group hurtles towards commercialization of its Hepatitis C (HCV) ID Kit.

AIM-quoted Genedrive published the results of a performance study in Africa earlier this week which demonstrated the “robust performance” of the handheld device in a third party setting and on territory precise instances.

‘Good progress’ with hep C test

Back in September the HCV ID Kit – which can test for the virus much more quickly and easily than what is currently out there – was awarded an all-important CE mark which meant it could be sold into Europe as well as any other country that accept CE certification under their national regulations.

The wheels of commercialization were really set in motion towards the end of 2017 when genedrive signed a distribution agreement with Sysmex which will see the latter market and sell the ID Kit and Genedrive platform in the EMEA region, with an initial focus on Africa where the virus is particularly prevalent.

“We are making good development with the launch of the CE marked Genedrive HCV ID kit,” said chief executive Budd.

“This is an exciting period of development and evolution for Genedrive as we transition to a commercial stage point of care Diagnostics Company.”